ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1209

Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors

Beatriz Frade-Sosa1, Andrés Ponce2, Roberto Gumucio3, José inciarte-Mundo4, María Torradeflot5, Virginia Ruiz-Esquide3, Rosa Morlà2, Ana Belén Azuaga6, Núria Sapena2, Marta Bassas2, Julio Ramirez3, Juan D Cañete6, Jose A Gomez-Puerta1 and Raimon Sanmarti1, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology Department, Hospital Clínic, Barcelona, Spain, 3Rheumatology departmen. Hospital Clinic de Barcelona, Barcelona, Spain, 4Institut d'Investigacions Biomèdiques August Pi i Sunyer,( IDIBAPS), Barcelona, Spain, 5Immunology Department, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain, 6Rheumatology Department, Hospital Clinic, Barcelona, Spain

Meeting: ACR Convergence 2021

Keywords: calprotectin, Il6 inhibitor, Jak inhibitor, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on acute phase reactants (AFR) such as C reactive protein (CRP) in rheumatoid arthritis (RA). However, CRP serum levels do not correlate with inflammatory activity in RA patients under IL6i therapy. JAK inhibitors (JAKi) also partly inhibit IL6 signaling. Calprotectin is a protein that correlates closely with inflammatory activity and may be a biomarker that accurately reflects the disease status in IL6i and JAKi treated RA patients.

Methods: Cross-sectional study in RA patients (ACR/EULAR 2010) treated with IL6i (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Demographic, serological data (autoantibodies, ESR, ultrasensitive CRP (usCRP), composite activity indices (DAS28, SDAI, CDAI, RAPID3), disability (HAQ) and therapy were evaluated. Plasma calprotectin levels were measured by ELISA (CALPROLAB ALP Menarini). Hand ultrasound was studied to calculate synovial hypertrophy (SH), power Doppler signal (PD) score and total ultrasound activity score (SH+PD) graded according to Szudlarek’s(1) . We compared plasma calprotectin and clinical and ultrasound variables in patients receiving IL6i and JAKi using Spearman’s correlation test.

Results: We included 78 patients (91% female, median age 58.9 years, median RA duration 14.5 years, 88.5% seropositive (RF and/or ACPA). Fifty two patients were treated with IL6i and 26 with JAKi [Table 1]. Ultrasound studies were made in 63 patients (42 receiving IL6i and 21 JAKi).

No significant between-group differences were observed in the TJC28, SJC28, CDAI, SDAI, and HAQ. DAS28 was higher in JAKi patients. There were no differences in ultrasound scores. The median (range) of plasma calprotectin was 0.36 μg/ml (0.12-2.39) in IL6i patients and 0.65 μg/ml (0.19-5.51) in JAKi patients (p=0.083) [Table 1].

In IL6i patients, plasma calprotectin weakly correlated with SJC28 but not with composite activity indices or with AFR (usCRP or ESR), although there was a significant correlation with all ultrasound scores (SH, PD and SH+PD) that was not found with usCRP or ESR. In JAKi patients, calprotectin showed a non-significant trend to correlation with TJC28, and a high correlation with all ultrasound scores (SH, PD and SH +PD) and usCRP levels, but not with activity indices [Table2].

Classification according to CDAI ≤10 vs. CDAI >10 showed no significant differences in calprotectin values: median (range) 0.33μg/ml (0.14-5.51) vs 0.59 μg/ml (0.12-5.50) p= 0.121). Classification according to ultrasound activity (ultrasound synovitis (SH ≥ 2 + PD≥1) in ≥ 1 joint showed -higher calprotectin levels in patients with ultrasound synovitis: median 0.70 μg/ml (0.18-5.03) vs 0.29 μg/ml (0.19-0.69) p< 0.001).

Conclusion: Plasma calprotectin in patients with low-moderate disease activity treated with IL6i or JAKi did not identify patients according to the degree of inflammation measured by the composite activity indices. However, in both groups and specially in patients treated with JAKi, calprotectin was related to ultrasound synovitis scores. Plasma calprotectin might be a biomarker of active synovitis in these patients.

TJC: tender joint count; SJC: swollen joint count; PGA: patient global assessment PhGA: physician global assessment; VAS visual analogue scale SH: synovial hypertrophy on ultrasound: PD power Doppler signal on ultrasound. Data expressed as median and (ranges)

Rho: Spearman’s correlation coefficient


Disclosures: B. Frade-Sosa, None; A. Ponce, Pfizer, 6, Lilly, 6; R. Gumucio, None; J. inciarte-Mundo, None; M. Torradeflot, None; V. Ruiz-Esquide, None; R. Morlà, None; A. Azuaga, None; N. Sapena, None; M. Bassas, None; J. Ramirez, None; J. Cañete, Abbvie, 6, Pfizer, 6, Janssen, 6; J. Gomez-Puerta, Abbvie, 6, BMS, 6, GSK, 6, Galapagos, 6, Lilly, 6, MSD, 6, Pfizer, 6, Roche, 6, Sanofi, 1; R. Sanmarti, Abbvie, 6, BMS, 5, BMS, 6, Sandoz, 6, Pfizer, 6, Roche, 6, MSD, 6.

To cite this abstract in AMA style:

Frade-Sosa B, Ponce A, Gumucio R, inciarte-Mundo J, Torradeflot M, Ruiz-Esquide V, Morlà R, Azuaga A, Sapena N, Bassas M, Ramirez J, Cañete J, Gomez-Puerta J, Sanmarti R. Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/plasma-calprotectin-as-a-biomarker-of-active-synovitis-in-rheumatoid-arthritis-a-clinical-and-ultrasound-study-in-patients-treated-with-il6-and-jak-inhibitors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-calprotectin-as-a-biomarker-of-active-synovitis-in-rheumatoid-arthritis-a-clinical-and-ultrasound-study-in-patients-treated-with-il6-and-jak-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology